The NCI-MATCH trial: lessons for precision oncology

被引：57

作者：

O'Dwyer, Peter J. ^{[1
]}

Gray, Robert J. ^{[2
]}

Flaherty, Keith T. ^{[3
]}

Chen, Alice P. ^{[4
]}

Li, Shuli ^{[2
]}

Wang, Victoria ^{[2
]}

McShane, Lisa M. ^{[5
]}

Patton, David R. ^{[6
]}

Tricoli, James V. ^{[4
]}

Williams, P. Mickey ^{[7
]}

Iafrate, A. John ^{[3
]}

Sklar, Jeffrey ^{[8
]}

Mitchell, Edith P. ^{[9
]}

Takebe, Naoko ^{[4
]}

Sims, David J. ^{[7
]}

Coffey, Brent ^{[6
]}

Fu, Tony ^{[7
]}

Routbort, Mark ^{[10
]}

Rubinstein, Larry V. ^{[5
]}

Little, Richard F. ^{[4
]}

Arteaga, Carlos L. ^{[11
]}

Marinucci, Donna ^{[12
]}

Hamilton, Stanley R. ^{[13
]}

Conley, Barbara A. ^{[14
]}

Harris, Lyndsay N. ^{[14
]}

Doroshow, James H. ^{[4
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] ECOG ACRIN Biostat Ctr, Dana Farber Canc Inst, Boston, MA USA

[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[4] NCI, Div Canc Treatment & Diag, Bethesda, MD USA

[5] NCI, Biometr Res Program, Div Canc Treatment & Diag, Bethesda, MD USA

[6] NCI, Ctr Biomed Informat & Informat Technol, Bethesda, MD USA

[7] Frederick Natl Lab Canc Res, Frederick, MD USA

[8] Yale Univ, New Haven, CT USA

[9] Thomas Jefferson Univ Hosp, Philadelphia, PA USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[11] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[12] ECOG ACRIN Canc Res Grp, Philadelphia, PA USA

[13] City Hope Natl Med Ctr, Duarte, CA USA

[14] NCI, Canc Diag Program, Div Canc Treatment & Diag, Bethesda, MD USA

来源：

NATURE MEDICINE | 2023年 / 29卷 / 6期

关键词：

PHASE-II; SOLID TUMORS; CANCERS; BRAF; VEMURAFENIB; INHIBITION; VALIDATION; TRAMETINIB; MUTATIONS; THERAPY;

D O I：

10.1038/s41591-023-02379-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The NCI-MATCH (Molecular Analysis for Therapy Choice) trial () was launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial-largely for patients with treatment-refractory, malignant solid tumors. Having completed in 2023, it remains one of the largest tumor-agnostic, precision oncology trials undertaken to date. Nearly 6,000 patients underwent screening and molecular testing, with a total of 1,593 patients (inclusive of continued accrual from standard next-generation sequencing) being assigned to one of 38 substudies. Each substudy was a phase 2 trial of a therapy matched to a genomic alteration, with a primary endpoint of objective tumor response by RECIST criteria. In this Perspective, we summarize the outcomes of the initial 27 substudies in NCI-MATCH, which met its signal-seeking objective with 7/27 positive substudies (25.9%). We discuss key aspects of the design and operational conduct of the trial, highlighting important lessons for future precision medicine studies.

引用

页码：1349 / 1357

页数：9

共 50 条

[21] Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial
Servant, Nicolas
Romejon, Julien
Gestraud, Pierre
La Rosa, Philippe
Lucotte, Georges
Lair, Severine
Bernard, Virginie
Zeitouni, Bruno
Coffin, Fanny
Jules-Clement, Gerome
Yvon, Florent
Lermine, Alban
Poullet, Patrick
Liva, Stephane
Pook, Stuart
Popova, Tatiana
Barette, Camille
Prud'homme, Franois
Dick, Jean-Gabriel
Kamal, Maud
Le Tourneau, Christophe
Barillot, Emmanuel
Hupe, Philippe
FRONTIERS IN GENETICS, 2014, 5
[22] Melanoma as a model for precision medicine in oncology
Kaufman, Howard L.
LANCET ONCOLOGY, 2014, 15 (03): : 251 - 252
[23] Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
McCourt, Carolyn K.
Gross, Jacob
Kalinsky, Kevin
Guan, Ping
McShane, Lisa M.
Wang, Victoria
O'Dwyer, Peter J.
Lahey, Matthew T.
Maican, Cayden
Bu, Xiangning
Patton, David
Harris, Lyndsay N.
JCO PRECISION ONCOLOGY, 2025, 9
[24] Precision medicine in pediatric oncology: Lessons learned and next steps
Mody, Rajen J.
Prensner, John R.
Everett, Jessica
Parsons, D. Williams
Chinnaiyan, Arul M.
PEDIATRIC BLOOD & CANCER, 2017, 64 (03)
[25] Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Gouda, Mohamed A.
Wei, Zihan
Rodon, Jordi
Davies, Michael A.
Janku, Filip
Gray, Robert J.
Wang, Victoria
Mcshane, Lisa M.
Rubinstein, Larry V.
Patton, David R.
Williams, P. Mickey
Hamilton, Stanley R.
Liu, Raymond
Bota, Daniela A.
Swiecicki, Paul L.
Buchschacher, Gary L.
Tricoli, James V.
Conley, Barbara A.
Arteaga, Carlos L.
Harris, Lyndsay N.
O'Dwyer, Peter J.
Chen, Alice P.
Flaherty, Keith T.
JCO PRECISION ONCOLOGY, 2025, 9
[26] CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
Hlevnjak, Mario
Schulze, Markus
Elgaafary, Shaymaa
Fremd, Carlo
Michel, Laura
Beck, Katja
Pfuetze, Katrin
Richter, Daniela
Wolf, Stephan
Horak, Peter
Kreutzfeldt, Simon
Pixberg, Constantin
Hutter, Barbara
Ishaque, Naveed
Hirsch, Steffen
Gieldon, Laura
Stenzinger, Albrecht
Springfeld, Christoph
Smetanay, Katharina
Seitz, Julia
Mavratzas, Athanasios
Brors, Benedikt
Kirsten, Romy
Schuetz, Florian
Froehling, Stefan
Sinn, Hans-Peter
Jaeger, Dirk
Thewes, Verena
Zapatka, Marc
Lichter, Peter
Schneeweiss, Andreas
JCO PRECISION ONCOLOGY, 2021, 5 : 676 - 686
[27] Precision medicine in pediatric oncology
Forrest, Suzanne J.
Geoerger, Birgit
Janeway, Katherine A.
CURRENT OPINION IN PEDIATRICS, 2018, 30 (01) : 17 - 24
[28] Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial
Allen, Carl E.
Laetsch, Theodore W.
Mody, Rajen
Irwin, Meredith S.
Lim, Megan S.
Adamson, Peter C.
Seibel, Nita L.
Parsons, D. Williams
Cho, Y. Jae
Janeway, Katherine
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (05):
[29] Clinical tumour sequencing for precision oncology: time for a universal strategy
Cheng, Michael L.
Berger, Michael F.
Hyman, David M.
Solit, David B.
NATURE REVIEWS CANCER, 2018, 18 (09) : 527 - 528
[30] Precision Oncology: Evolving Clinical Trials across Tumor Types
Song, I-Wen
Vo, Henry Hiep
Chen, Ying-Shiuan
Baysal, Mehmet A.
Kahle, Michael
Johnson, Amber
Tsimberidou, Apostolia M.
CANCERS, 2023, 15 (07)

← 1 2 3 4 5 →